MA48862A - Méthode de traitement de tumeur immunothérapeutique - Google Patents

Méthode de traitement de tumeur immunothérapeutique

Info

Publication number
MA48862A
MA48862A MA048862A MA48862A MA48862A MA 48862 A MA48862 A MA 48862A MA 048862 A MA048862 A MA 048862A MA 48862 A MA48862 A MA 48862A MA 48862 A MA48862 A MA 48862A
Authority
MA
Morocco
Prior art keywords
treatment method
tumor treatment
immunotherapeutic
immunotherapeutic tumor
tumor
Prior art date
Application number
MA048862A
Other languages
English (en)
Inventor
Neel K Anand
Haiying Cai
Bo-Liang Deng
Marlene Hennessy
Bhalchandra V Joshi
Saul Kivimae
Zhongxu Ren
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MA48862A publication Critical patent/MA48862A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
MA048862A 2017-05-02 2018-05-02 Méthode de traitement de tumeur immunothérapeutique MA48862A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762500486P 2017-05-02 2017-05-02
US201762502051P 2017-05-05 2017-05-05

Publications (1)

Publication Number Publication Date
MA48862A true MA48862A (fr) 2020-04-01

Family

ID=64016803

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048862A MA48862A (fr) 2017-05-02 2018-05-02 Méthode de traitement de tumeur immunothérapeutique

Country Status (10)

Country Link
US (1) US20210292425A1 (fr)
EP (1) EP3628010A4 (fr)
JP (1) JP7165680B2 (fr)
KR (1) KR20190141760A (fr)
CN (1) CN110582300A (fr)
AU (1) AU2018261102A1 (fr)
CA (1) CA3062291A1 (fr)
MA (1) MA48862A (fr)
MX (1) MX2019013071A (fr)
WO (1) WO2018204528A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021524756A (ja) 2018-05-14 2021-09-16 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なサイトカインポリペプチド及びその使用方法
SG11202011349PA (en) 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable interleukin-2 polypeptides and methods of use thereof
CN113905758A (zh) * 2019-04-05 2022-01-07 大日本住友制药株式会社 水溶性佐剂和含有其的组合物
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
US20220370563A1 (en) * 2019-10-25 2022-11-24 Neoleukin Therapeutics, Inc. Methods of administration of il-2 receptor agonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10248141B4 (de) * 2002-10-11 2007-04-19 Universitätsklinikum Hamburg-Eppendorf Nukleinsäuren und deren Verwendung für die Gentherapie
EP2572715A1 (fr) * 2002-12-30 2013-03-27 3M Innovative Properties Company Combinaisons immunostimulantes
US20080241139A1 (en) * 2006-10-31 2008-10-02 Regents Of The University Of Colorado Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
KR20130036246A (ko) * 2010-05-07 2013-04-11 베일러 리서치 인스티튜트 사람 ｃｄ8+ ｔ 세포의 수지상 세포 면역수용체(ｄｃｉｒ)-매개 교차프라이밍
WO2012088422A1 (fr) * 2010-12-22 2012-06-28 Nektar Therapeutics Conjugués promédicaments polymères à plusieurs bras de composés à base de taxane
CN103458924A (zh) * 2011-02-10 2013-12-18 路易斯维尔大学研究基金会有限公司 含有4-1bbl的佐剂组合物
PL3134123T3 (pl) * 2014-02-21 2021-07-12 Nektar Therapeutics (India) Pvt. Ltd. Agoniści selektywni względem IL-2Rbeta w kombinacji z przeciwciałem anty-CTLA-4 lub z przeciwciałem anty-PD-1
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP7250679B2 (ja) * 2017-01-10 2023-04-03 ネクター セラピューティクス Ｔｌｒ作動薬化合物のマルチアームポリマーコンジュゲート及び関連の免疫療法治療の方法
EP3668548A2 (fr) * 2017-08-17 2020-06-24 Nektar Therapeutics Méthode immunothérapeutique de traitement de tumeur

Also Published As

Publication number Publication date
AU2018261102A1 (en) 2019-11-07
US20210292425A1 (en) 2021-09-23
JP2020518610A (ja) 2020-06-25
CA3062291A1 (fr) 2018-11-08
CN110582300A (zh) 2019-12-17
MX2019013071A (es) 2019-12-11
KR20190141760A (ko) 2019-12-24
JP7165680B2 (ja) 2022-11-04
EP3628010A4 (fr) 2021-02-17
WO2018204528A1 (fr) 2018-11-08
EP3628010A1 (fr) 2020-04-01

Similar Documents

Publication Publication Date Title
MA46771A (fr) Méthode de traitement de tumeur immunothérapeutique
MA50056A (fr) Procédés de traitement de tumeur
HK1258098A1 (zh) 治療癌症的方法
IL275663A (en) Cancer treatment methods
HK1251409A1 (zh) 治療癌症的方法
MA43374A (fr) Méthodes de traitement de tumeurs malignes
ZA201804227B (en) Methods of treating cancer
MA48862A (fr) Méthode de traitement de tumeur immunothérapeutique
MA46361A (fr) Traitement du cancer de la prostate
IL262342A (en) Cancer treatment methods
MA47408A (fr) Traitement du cancer
MA45780A (fr) Méthodes de traitement du cancer de la prostate
HK1247818A1 (zh) 治療疾病的方法
KR102377742B1 (ko) 암치료약
EP3644062C0 (fr) Procédé de prédiction de réponse d'un cancer de l' oesophage à une thérapie par anticorps anti-erbb3
ZA201908539B (en) Method of treatment of cancer
MA52627A (fr) Traitement du cancer
FR3039368B1 (fr) Procede de traitement cosmetique
GB201706406D0 (en) Method of treatment
BR112016015712A2 (pt) método de tratamento de doenças hepáticas.
SG11202005163PA (en) Methods of treating cancer
DK3576740T3 (da) Cancerbehandling
DK3407909T3 (da) Cancerbehandling
GB201602802D0 (en) Method of treatment
HK1243937A1 (zh) 治療疾病的方法